HOUSTON – (Oct. 31, 2019) – A combination of drugs that affect mitochondria — the power plants inside cells — may become the best weapons yet to fight acute myeloid leukemia, according to Rice University researchers.
A study led by Rice bioscientist Natasha Kirienko and postdoctoral researcher Svetlana Panina found that mitocans, anti-cancer drugs that target mitochondria, are particularly adept at killing leukemia cells, especially when combined with a glycolytic inhibitor, while leaving healthy blood cells in the same sample largely unaffected.
Their open access paper, a collaboration with the University of Texas MD Anderson Cancer Center, appears in the Nature journal Cell Death & Disease. The research could lead to new ways to personalize treatment for patients with leukemia.
“We started with the idea of finding an underlying connection between types of cancer and their sensitivity to specific kinds of chemotherapeutics, mitochondria-targeting drugs,” Kirienko said. “Our bioinformatic analysis, which included 60 cell lines from nine different cancer types, showed that leukemia cells are particularly sensitive to mitochondrial damage.”
The researchers exposed the cell lines to multiple known mitocan molecules. They found low doses of a mitocan/glycolytic inhibitor cocktail killed all of the leukemia cell lines they tested at concentrations lower than what was necessary to kill healthy cells. Conversely, they reported that solid tumor cells, like ovarian cancers, proved highly resistant to mitocans. Glioblastoma cells were sensitive to mitocans, but unfortunately more resistant than healthy blood cells.
In their best experimental results, 86% of targeted leukemia cells were killed, compared to only 30% of healthy blood cells. “A number of drugs currently used in the clinic have some cancer preference, but here we’re talking about a five-fold difference in survival,” Kirienko said.
The researchers also showed a significant correlation between how efficiently mitochondria can turn energy from incoming oxygen into useful adenosine triphosphate (ATP) and how resistant they are to treatment.
“The more efficient they are, the more resistant they will be to mitochondria-targeting drugs,” Kirienko said. “If this holds true, doctors can perform a relatively simple test of this specific parameter of mitochondrial health from a patient’s sample and predict whether the treatment would be effective.”
Panina said computational models led them to think the glycolysis pathway could be enlisted to help mitocans. “Glycolysis also provides ATP, so targeting that will decrease energy as well as block the precursor for energy production in mitochondria, which mitocans will exacerbate further,” she said. “It led us to believe this combination would have a synergistic effect.
“Cancer cells are usually more metabolically active than normal cells, so we predicted that they be might be more sensitive to this combined strike, and they are,” Panina said.
Kirienko said a presentation of the research she and Panina gave at MD Anderson’s recent Metabolism in Cancer Symposium drew a large response. “People were very interested, and they immediately started asking, ‘Did you test my favorite drug or combination?’ and ‘Are you going to test it in a wider panel of cancers?’”
That work is well underway, Panina said. “We’re currently doing high-throughput screening of these potential synergistic drug combinations against leukemia cells,” she said. “We’ve gone through 36 combinations so far, building landscapes for each one.”
“And we found some that are more effective than what’s reported in this paper,” Kirienko added. “But we’ve also found some that are antagonistic — two drugs that negate each other’s effects — so it’s also important to know what therapeutic cocktails should not go together.”
Co-authors of the paper are postdoctoral fellow Natalia Baran; Marina Konopleva, a physician-scientist and professor in the Department of Leukemia at MD Anderson; and Rice graduate student Fabio Brasil da Costa. Kirienko is an assistant professor of biosciences.
The Cancer Prevention Research Institute of Texas, the Welch Foundation and the National Institutes of Health supported the research.
Read the paper at https://www.nature.com/articles/s41419-019-1851-3.pdf.
Our Dr. Cheng-En Hsieh explains why radiation-induced liver disease is an important factor to consider during #livercancer treatment: https://t.co/M18QvNAneT @cure_magazine #endcancer
RT @bcm_ocd: So excited to have Dr. Jeff Wood present the results of our NIH funded study examining personalized CBT vs. standard care CBT…
RT @BCMHoustonJobs: We're hiring! Read about our latest job opening here: Instructor - Nurse Practitioner - https://t.co/ZKY1iNNTuY #Health…
RT @BCMHouston_News: How can you tell if your baby caught a cold and how long will the symptoms last? @bcmhouston and @TexasChildrens exper…
Today’s #VeteranOfTheDay is Army Veteran Louis D. Brinner, who served as a rifleman in Europe during WWII and turns 100 Nov. 22: https://t.co/g8CQSNuLTI
At @TexasChildrens, we know all about helping children and their families through stressful times like surgeries. Take a look at these helpful tools to use as you prepare for your child's surgery: https://t.co/4wyHxbjcxe https://t.co/xBp95faWly
Even though this lightweight material is full of holes, it's nearly as hard as diamond and stops bullets better than solid materials: https://t.co/N1QBG6C6yz https://t.co/XKyesrwt6c
@ShirleyHelenTx We're sending good vibes your way, Shirley. Please let us know if your husband needs anything while he's here.
A "silent heart attack" is caused by ischemia, a temporary blood shortage. Sometimes the shortage causes the pain of angina pectoris. But in other cases, there is no pain. These cases are called silent ischemia, or "silent heart attacks." https://t.co/UKu4mglkKJ
After seeing photos of herself from a family celebration, Adriana Mercado was shocked at how unhealthy she looked. Now, thanks to a walking routine, she’s lost 70 pounds and improved her overall health: https://t.co/dx7z4STihG @FocusedonHealth #endcancer https://t.co/NVmGyo6r8W
University of Houston@UHouston
Coogs, we love you ❄️SNOW❄️ much! Happy #CougarRedFriday https://t.co/d43lBGfJBX
@debadrita_j Thank you!
VA, Prostate Cancer Foundation seek solutions for aggressive prostate cancer https://t.co/uGXX5vPImo via #VAntagePoint
@debadrita_j This is beautiful! Can we share this on Instagram and credit you?
RT @UTH_CVSurgery: Congratulations to Dr. Anthony Estrera @estrera_md, honored and appointed the Hazim J. Safi, MD, Distinguished Chair in…